DOCSLIB.ORG

Von Recklinghausen's Neurofibromatosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Von Recklinghausen's Neurofibromatosis Br J Ophthalmol: first published as 10.1136/bjo.62.9.604 on 1 September 1978. Downloaded from British Journal of Ophthalmology, 1978, 62, 604-608 Von Hippel's disease in association with von Recklinghausen's neurofibromatosis JOHN V. THOMAS, PETER L. SCHWARTZ, AND EVANGELOS S. GRAGOUDAS From the Retina Service, Massachusetts Eye and Ear Infirmary, and the Eye Research Institute of Retina Foundation, Boston, Massachusetts SUMMARY Ten members of a large family who showed manifestations of either von Hippel-Lindau disease or von Recklinghausen's neurofibromatosis were examined. Three of 10 members were found to have retinal angiomas which had not been present on fundus examination 3 years previously. These angiomas were associated with ocular and systemic signs of neurofibromatosis. These cases show overlapping manifestations of different phakomatoses and provide support for the concept of a common aetiology for these diseases. In 1923 Van der Hoeve introduced the term 'phako- of severe headaches and projectile vomiting. Physical matoses' to describe a heredofamilial group of examination at that time showed a normal blood diseases characterised by the presence of dissemin- pressure, numerous large caf6-au-lait spots, and ated hamartomas (Van der Hoeve, 1923). The 6 axillary freckles. Cutaneous neurofibromas were diseases that constitute this group are tuberous not present. Ocular examination showed normal sclerosis or Bourneville's disease, von Reckling- retinal vasculature in both fundi. Family history by copyright. hausen's neurofibromatosis, von Hippel-Lindau revealed that her mother had overlapping mani- disease, meningocutaneous angiomatosis or Sturge- festations of Lindau's disease and von Reckling- Weber syndrome, ataxia-telangiectasia or Louis-Bar hausen's neurofibromatosis proved at necropsy. A syndrome, and arteriovenous communication of pneumoencephalogram and ventriculogram showed retina and brain or Wyburn-Mason syndrome hydrocephalus with aqueductal stenosis and a mass (Yanoff and Fine, 1975). The term von Hippel's in the thalamic area on the left side. Owing to her disease refers to retinal angiomatosis not occurring skin lesions and the family history of neurofibro- in association with a vascular tumour of the central matosis the thalamic mass was thought to be a nervous system. Similarities in inheritance patterns glioma, though a tissue diagnosis was not made. http://bjo.bmj.com/ and affected germ layers have been noted among Radiation therapy was begun at this time. The the phakomatoses. However, each has distinctive patient's hospital course was complicated by clinical features, and reports of overlapping mani- meningitis, malfunctioning shunts, and paraplegia festations of 2 phakomatoses in the same individual secondary to arachnoiditis. or family are uncommon (Fracassi and Parachu, At age 14 years ophthalmoscopic examination 1935; Chapman et al., 1959; Melmon and Rosen, revealed a visual acuity of RE 10/30 and LE 12/30. 1964). The fundi were normal except for resolving papil- The present report adds 3 new cases of von loedema of the left optic disc. Two years after onset on September 25, 2021 by guest. Protected Hippel's disease from a large family (Fig. 1) with of symptoms the patient had marked limitation of known overlapping signs of von Hippel-Lindau intellectual and motor functions. disease and von Recklinghausen's neurofibromatosis. In March 1977 the patient was referred to the Massachusetts Eye and Ear Infirmary for evaluation Case reports of a 'greenish mass' in the left eye. Ocular examina- tion showed a visual acuity of RE 20/50 and LE CASE 1 hand motions at 1 ft (30 cm). Forty-five prism (Subject IV-17 in Fig. 1). A 17-year-old woman was dioptres of left exotropia and a Gunn pupillary admitted to a hospital at the age of 13 for evaluation reaction in the left eye were present. Slit-lamp examination revealed multiple iris naevi in both Address for reprints: Dr John V. Thomas, Eye Pathology eyes. Fundus examination of the right eye showed Laboratory, Wilmer Ophthalmological Institute, Johns Hopkins University Hospital, 601 North Broadway, Balti- retinal angiomas in 3 areas (Figs. 2, 3, 4). A non- more, Maryland, USA rhegmatogenous retinal detachment sparing the 04 Br J Ophthalmol: first published as 10.1136/bjo.62.9.604 on 1 September 1978. Downloaded from Von Hippel's disease in association with von Recklinghausen's neurofibromatosis 605 macular area was present in both inferior quadrants gland. His blood pressure was 130/80 mmHg. and in the superonasal quadrant. Considerable Examination of his skin showed more than 6 caf&- vitreous membrane formation was present overlying au-lait spots. One subcutaneous nodule was present the angiomas in the superonasal quadrant (Fig. 2). on the right leg. Fundus examination of the left eye showed a Ocular examination showed that the visual acuity long-standing total retinal detachment partially was 20/25 in both eyes. Applanation tensions were obscured by old vitreous haemorrhage. A red mass 15 mmHg in the right eye and 19 mmHg in the left. seen in the superonasal quadrant was thought to be On biomicroscopy numerous iris naevi were seen, a retinal angioma. The patient was admitted to and fundus examination showed retinal angiomas hospital for surgical treatment of retinal detach- in both eyes (Figs. 7, 8). ment, and a preoperative neurological evaluation, including computerised axial tomography (CAT) CASE 3 scan, revealed a large left thalamic mass which was (Subject IV-16 in Fig. 1). A 20-year-old woman was consistent with the diagnosis of thalamic glioma. examined 3 years previously and was found to have Cryotherapy of the retinal angiomas combined signs of neurofibromatosis and normal ocular fundi. with scleral buckling was successfully performed on The patient complained of occasional headaches the right eye. but denied other neurological symptoms. Her blood A shave skin biopsy of a caf&-au-lait spot from pressure was 158/84 mmHg. Examination of her the left arm was obtained (Fig. 5) and sent for elec- skin showed 3 cafe-au-lait spots measuring greater tron microscopic examination in order to establish than 1-5 cm each. Multiple small cutaneous neuro- a tissue diagnosis of von Recklinghausen's neuro- fibromas were noted. fibromatosis. This showed macromelanosomes in Ocular examination revealed a visual acuity of melanocytes of the epidermis (Fig. 6). RE 20/20 and LE 20/25. Intraocular pressure by applanation tonometry was 21 mmHg in the right CASE 2 eye and 16 mmHg in the left eye. Slit-lamp examina- (Subject IV-18 in Fig. 1). A 14-year-old boy was tion showed numerous iris naevi. Ophthalmoscopy by copyright. examined 3 years before the present examination, revealed a retinal angioma in the superonasal at which time signs of neurofibromatosis were quadrant of the fundus of the right eye. The left found, while both fundi appeared normal. CAT-scan fundus was within normal limits. examination 2 months previously was negative for intracranial lesions. The patient complained of Discussion occasional headaches but denied other neurological symptoms. He had no symptoms referable to his The phakomatoses are syndromes of hereditary kidneys, adrenal glands, pancreas, or thyroid origin; all except the Louis-Bar syndrome are http://bjo.bmj.com/ on September 25, 2021 by guest. Protected Male Female Normal Z 0 Necropsy and clinical data *0 Examined [e] ® von Hlippel- Lindau disease n 0 Neurofibromatosis and von Hippel- 0 Deceased 0 Lindau disease Neurofibromatosis * 0 Cousins Fig. 1 Pedigree ofa family, certain members of which have von Recklinghausen's neurofibromatosis, von Hippel-Lindau disease, or a combined syndrome (reprintedfrom Neurology, 25, 840-4, with permission from Dr P. Tishler) Br J Ophthalmol: first published as 10.1136/bjo.62.9.604 on 1 September 1978. Downloaded from 606 John V. Thomas, Peter L. Schwartz, and Evangelos S. Gragoudas Fig. 2 Retinal angiomas with dilated vessels and Fig. 3 Retinal angioma in inferotemporal quadrant of overlapping membranes in superonasal quadrant of right right eye in Case I eye in Case I by copyright. Fig. 4 Retinal angioma in inferonasal quadrant ofright Fig. 5 Typical cafi-au-lait spot in von Recklinghausen's http://bjo.bmj.com/ eye in Case 1 neurofibromatosis from Case 1 on September 25, 2021 by guest. Protected Fig. 7 Retinal angioma in inferior portion offundus of Fig.F 8 Retinal angioma in inferotemporal quadrant of right eye in Case 2 funds ofleft eye in Case 2 Br J Ophthalmol: first published as 10.1136/bjo.62.9.604 on 1 September 1978. Downloaded from Von Hippel's disease in association with von Recklinghausen's neurofibromatosis 607 Fig. 6 Electron micrograph of skin biopsy ofcafi-au-lait spot in Case 1. Macromelanosomes (MM) in melanocyte (MEL) in epidermis are seen. Adjacent epidermal cells (E) containing melanosomes ofnormal size (NM) are present. Basement membrane separates epidermis from underlying dermis (original magnification x 16 000) transmitted in an autosomal dominant fashion. neurofibromatosis and retinal angiomas in the They are known to have individually characteristic ophthalmic literature (Frenkel, 1967; Wolter, 1965). clinical and pathological features which have been In the latter case the angiomas were solitary. well described (Boder and Sedgwick, 1958; Alexan- Von Recklinghausen's neurofibromatosis is known by copyright. der and Norman, 1960; Melmon and Rosen, 1964; to involve the skin, nervous system, bones, endocrine Harley and Grover, 1970; Font and Ferry, 1972; glands, and eyes.
Load more

Recommended publications
  • Network Scan Data
    CTEP Protocol No: T-99-0090 CC Protocol No: 01-C-0222 Amendment: J Revised: 4/21/09 IRB Approval Date: A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Coordinating Center: Pediatric Oncology Branch, NCI Principal Investigator: Brigitte Widemann, M.D.* (POB, NCI) NIH Associate Investigators: Frank M. Balis, M.D. (POB, NCI) Beth Fox, M.D. (POB, NCI) Kathy Warren, M.D. (NOB, NCI) Andy Gillespie, R.N. (ND, CC) Eva Dombi, MD (POB, NCI)** Nalini Jayaprakash, (POB, NCI) Diane Cole, (POB, NCI) Seth Steinberg, Ph.D. (BDMB, DCS, NCI) Nicholas Patronas, M.D. (DR, CC)** Maria Tsokos, M.D., (Laboratory of Pathology, NCI)** Pamela Wolters, Ph.D. (HAMB, NCI) Staci Martin, Ph.D. (HAMB, NCI) Jeffrey Solomon, (NIH and Sensor Systems, Inc.) Non-NIH Associate Investigators: Wanda Salzer, M.D. ** Keesler Air Force Base, Biloxi, Mississippi) 81st MDOS/SGOC 301 Fisher Street, Room 1A132 Keesler AFB, MS 39534-2519 Phone: 228-377-6524 E-mail: [email protected] Bruce R. Korf, M.D., Ph.D. ** Chair, Department of Genetics Univeristy of Alabama at Birmingham 1530 3rd Ave. S. Birmingham, AL 35294 Phone: (205)-934-9411, Fax: (205)-934-9488 E-mail: [email protected] David H. Gutmann, M.D., Ph.D. ** Department of Neurology Washington University School of Medicine St. Louis Children’s Hospital Box 8111, 660 S. Euclid Avenue St. Louis, MO 63110 Phone: (314)-632-7149, Fax: (314)-362-9462 E-mail: [email protected] 1 4/21/2009 T-99-0090, 01-C-0222 Arie Perry, M.D.
    [Show full text]
  • Depo-Provera
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ® DEPO-PROVERA medroxyprogesterone acetate injectable suspension, USP Sterile Aqueous Suspension 50 mg/mL and 150 mg/mL Progestogen Pfizer Canada Inc. Date of Revision: 17,300 Trans-Canada Highway February 13, 2018 Kirkland, Quebec H9J 2M5 Submission Control No: 210121 ® Pharmacia & Upjohn Company LLC Pfizer Canada Inc., Licensee © Pfizer Canada Inc., 2018 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION......................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS: ................................................................................ 5 ADVERSE REACTIONS ................................................................................................. 18 DRUG INTERACTIONS .................................................................................................. 27 DOSAGE AND ADMINISTRATION .............................................................................. 28 OVERDOSAGE ................................................................................................................ 30 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 30 STORAGE AND
    [Show full text]
  • Cutaneous Neurofibromas: Clinical Definitions Current Treatment Is Limited to Surgical Removal Or Physical Or Descriptors Destruction
    ARTICLE OPEN ACCESS Cutaneous neurofibromas Current clinical and pathologic issues Nicolas Ortonne, MD, PhD,* Pierre Wolkenstein, MD, PhD,* Jaishri O. Blakeley, MD, Bruce Korf, MD, PhD, Correspondence Scott R. Plotkin, MD, PhD, Vincent M. Riccardi, MD, MBA, Douglas C. Miller, MD, PhD, Susan Huson, MD, Dr. Wolkenstein Juha Peltonen, MD, PhD, Andrew Rosenberg, MD, Steven L. Carroll, MD, PhD, Sharad K. Verma, PhD, [email protected] Victor Mautner, MD, Meena Upadhyaya, PhD, and Anat Stemmer-Rachamimov, MD Neurology® 2018;91 (Suppl 1):S5-S13. doi:10.1212/WNL.0000000000005792 Abstract RELATED ARTICLES Objective Creating a comprehensive To present the current terminology and natural history of neurofibromatosis 1 (NF1) cuta- research strategy for neous neurofibromas (cNF). cutaneous neurofibromas Page S1 Methods NF1 experts from various research and clinical backgrounds reviewed the terms currently in use The biology of cutaneous fi for cNF as well as the clinical, histologic, and radiographic features of these tumors using neuro bromas: Consensus published and unpublished data. recommendations for setting research priorities Results Page S14 Neurofibromas develop within nerves, soft tissue, and skin. The primary distinction between fi fi Considerations for cNF and other neuro bromas is that cNF are limited to the skin whereas other neuro bromas development of therapies may involve the skin, but are not limited to the skin. There are important cellular, molecular, for cutaneous histologic, and clinical features of cNF. Each of these factors is discussed in consideration of neurofibroma a clinicopathologic framework for cNF. Page S21 Conclusion Clinical trial design for The development of effective therapies for cNF requires formulation of diagnostic criteria that cutaneous neurofibromas encompass the clinical and histologic features of these tumors.
    [Show full text]
  • 9Th Clinical Dermatology Congress Psoriasis, Psoriatic Arthritis & Skin
    conferenceseries.com Joint Conference Mi Hye Lee et al., J Clin Exp Dermatol Res 2017, 8:6 (Suppl) DOI: 10.4172/2155-9554-C1-066 9th Clinical Dermatology Congress & 2nd International Conference on Psoriasis, Psoriatic arthritis & Skin infections October 16-18, 2017 New York, USA Nonsurgical treatment using micro-insulated needle on neurofibroma Mi Hye Lee, Hak Tae Kim, Woo Jin Lee, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee and Jee Ho Choi University of Ulsan, Korea any studies have investigated the application of micro-insulated needles with radiofrequency (RF) for acne treatment or skin Mrejuvenation. However, there is no study investigating the effects of using micro-insulated needles with RF to treat multiple neurofibroma (NF) lesions. Many patients with multiple neurofibromas usually hesitate to remove all the lesions surgically due to cosmetic concerns. The aim of this study was to evaluate the clinicopathologic outcome, including efficacy and side effects after treatment, using newly developed micro-insulated needles with RF treatment. In this study, two human volunteers received multiple sessions of the micro-insulated needle RF treatment to multiple lesions. Seven to 40 shots were performed on each lesion. The treatment settings were as follows: microneedle penetrating depth of 5.0 mm; insulated 1.0 mm; power 16~46 (level 12~25); and a RF exposure time of 180~400 milliseconds. Skin biopsies were performed before and after the treatment. Outcome assessments included standardized photography, objective measurements of lesion size, histopathologic comparison between before and after the treatment, a physician’s global assessment, and patient satisfaction scores. RF energy could be delivered to the lesions without epidermal damage because the micro-insulation on the needle protects the epidermis from skin burns.
    [Show full text]
  • Clinical Guideline Treatment and Removal of Benign Skin Lesions
    Clinical Guideline Guideline Number: CG015, Ver. 5 Treatment and Removal of Benign Skin Lesions Disclaimer Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Oscar may delegate utilization management decisions of certain services to third-party delegates, who may develop and adopt their own clinical criteria. Clinical guidelines are applicable to certain plans. Clinical guidelines are applicable to members enrolled in Medicare Advantage plans only if there are no criteria established for the specified service in a Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) on the date of a prior authorization request. Services are subject to the terms, conditions, limitations of a member’s policy and applicable state and federal law. Please reference the member’s policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits) or contact Oscar at 855-672-2755 to confirm coverage and benefit conditions. Summary The integumentary system is comprised of the skin, hair, and nails. The skin is divided into two layers: the dermis and epidermis; diseases of these protective outer layers are among the most common conditions worldwide. Lesions of the skin can be either benign (non-malignant), pre-malignant (potential for evolving into malignancy), or malignant (cancerous). Such lesions arise from congenital malformations or are acquired, often due to extensive UV exposure or underlying illness. Diagnosis is primarily through history, clinical exam, and the appearance of the lesion(s). While the vast majority of benign lesions require no intervention, some cases may necessitate intervention due to bothersome symptoms, for definitive diagnosis, or for exclusion of malignant features.
    [Show full text]
  • Supermicar Data Entry Instructions, 2007 363 Pp. Pdf Icon[PDF
    SUPERMICAR TABLE OF CONTENTS Chapter I - Introduction to SuperMICAR ........................................... 1 A. History and Background .............................................. 1 Chapter II – The Death Certificate ..................................................... 3 Exercise 1 – Reading Death Certificate ........................... 7 Chapter III Basic Data Entry Instructions ....................................... 12 A. Creating a SuperMICAR File ....................................... 14 B. Entering and Saving Certificate Data........................... 18 C. Adding Certificates using SuperMICAR....................... 19 1. Opening a file........................................................ 19 2. Certificate.............................................................. 19 3. Sex........................................................................ 20 4. Date of Death........................................................ 20 5. Age: Number of Units ........................................... 20 6. Age: Unit............................................................... 20 7. Part I, Cause of Death .......................................... 21 8. Duration ................................................................ 22 9. Part II, Cause of Death ......................................... 22 10. Was Autopsy Performed....................................... 23 11. Were Autopsy Findings Available ......................... 23 12. Tobacco................................................................ 24 13. Pregnancy............................................................
    [Show full text]
  • A Case of Isolated Plexiform Neurofibroma in a Patient with Myasthenia Gravis
    Ann Dermatol (Seoul) Vol. 21, No. 1, 2009 CASE REPORT A Case of Isolated Plexiform Neurofibroma in a Patient with Myasthenia Gravis Seung Ju Back, M.D., Dae Hun Kim, M.D., Nari Kim, M.S., Young Lee, M.D., Young Joon Seo, M.D., Jang Kyu Park, M.D., Jeung Hoon Lee, M.D. Department of Dermatology, College of Medicine, Chungnam National University, Daejeon, Korea We report a case of an isolated plexiform neurofibroma often arising from the branches of a major nerve1. In this occurring in a patient with myasthenia gravis. A 48-year-old tumor, the nerve is converted into a convoluted mass man presented with asymptomatic skin-colored nodules on which has been likened to a 'bag of worms'. The the tip of his 4th finger. Microscopically, a plexiform plexiform neurofibroma is considered to be pathognomic neurofibroma was identified located in the dermis that of neurofibromatosis 1 (NF1)1,2. However, a few cases of appeared to originate from small superficial nerves. He had isolated plexiform neurofibroma that were not associated a 20-year history of treated myasthenia gravis; otherwise, his with NF1 have been reported. personal and family histories were unremarkable. Given that Myasthenia gravis is a relatively rare autoimmune disorder myasthenia gravis is a disorder of the peripheral nerves, of the peripheral nerves associated with pemphigus, plexiform neurofibromas could be associated with my- alopecia areata and psoriasis3-5. The development of an asthenia gravis. However, the development of an isolated isolated plexiform neurofibroma in myasthenia gravis has plexiform neurofibroma in a case of myasthenia gravis has not been reported.
    [Show full text]
  • NSJ-Spine January 2004
    Neurosurg Focus 22 (6):E25, 2007 Granular cell tumor: a rare tumor of the ulnar nerve Case report GAVIN A. DAVIS, M.B.B.S., F.R.A.C.S. Department of Neurosurgery, Cabrini Hospital, Victoria, Australia PGranular cell tumors of the ulnar nerve are extremely rare, with only two cases previously reported in the English literature. The author presents a case of granular cell tumor of the ulnar nerve, in which the tumor was resected and the nerve was repaired with a nerve graft. The histopathological characteristics, imaging findings, and clinical data regarding these tumors are reviewed, and based on all the available evidence, a new treatment paradigm is proposed, which differs from that used in the earlier reported cases and takes into account the reported rate of tumor recurrence after incomplete resection. KEY WORDS • granular cell tumor • nerve tumor • peripheral nerve • ulnar nerve ENIGN GRANULAR CELL TUMORS are uncommon tu- vated by the proximal ulnar nerve (the flexor carpi ulnaris mors that most frequently involve skin and subcu- and flexor digitorum profundus) were normal. Strength in B taneous tissue. Their involvement in major nerves the intrinsic hand muscles innervated by the ulnar nerve is exceptionally rare, and only two cases involving the ul- was LSUMC Grade 0, with the exception of the ulnar nar nerve have been identified in the English literature.2,9 nerve–innervated lumbrical muscles, in which it was Grade This report adds a new case of granular cell tumor involv- 2. Sensory examination revealed reduced sensation in the ing the ulnar nerve and reviews the previously published ulnar distribution, but sensory localization was still pres- cases in light of this most recent one.
    [Show full text]
  • Metalloproteinase 1 Downregulation in Neurofibromatosis 1
    Tsuji et al. Cell Death and Disease (2021) 12:513 https://doi.org/10.1038/s41419-021-03802-9 Cell Death & Disease ARTICLE Open Access Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine Gaku Tsuji1,2, Ayako Takai-Yumine 1, Takahiro Kato3 and Masutaka Furue1,2,4 Abstract Neurofibromatosis type 1 is an autosomal dominant genetic disorder caused by mutation in the neurofibromin 1 (NF1) gene. Its hallmarks are cutaneous findings including neurofibromas, benign peripheral nerve sheath tumors. We analyzed the collagen and matrix metalloproteinase 1 (MMP1) expression in Neurofibromatosis 1 cutaneous neurofibroma and found excessive expression of collagen and reduced expression of MMP1. To identify new therapeutic drugs for neurofibroma, we analyzed phosphorylation of components of the Ras pathway, which underlies NF1 regulation, and applied treatments to block this pathway (PD184352, U0126, and rapamycin) and lysosomal processes (chloroquine (CQ), hydroxychloroquine (HCQ), and bafilomycin A (BafA)) in cultured Neurofibromatosis 1 fibroblasts. We found that downregulation of the MMP1 protein was a key abnormal feature in the neurofibromatosis 1 fibroblasts and that the decreased MMP1 was restored by the lysosomal blockers CQ and HCQ, but not by the blockers of the Ras pathway. Moreover, the MMP1-upregulating activity of those lysosomal blockers was dependent on aryl hydrocarbon receptor (AHR) activation and ERK phosphorylation. Our findings suggest that lysosomal blockers are potential candidates for the treatment of Neurofibromatosis 1 neurofibroma. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Introduction manifestations are variable, unpredictable, and potentially Neurofibromatosis type 1 (Neurofibromatosis 1) is a life-threatening. Malignant peripheral nerve sheath tumors genetic disorder that affects one in 2600 to 4500 live are generally associated with a fatal outcome.
    [Show full text]
  • Multiple, Primary Brain Tumors with Diverse Origins
    Published online: 2019-09-02 Case Series Multiple, Primary Brain Tumors with Diverse Origins and Different Localizations: Case Series and Review of the Literature Thara Tunthanathip, Kanet Kanjanapradit1, Sanguansin Ratanalert, Nakornchai Phuenpathom, Thakul Oearsakul, Anukoon Kaewborisutsakul Department of Surgery, Background: Multiple, primary brain tumors with different histological types Neurosurgical Unit, Faculty occurring in the same patient are extremely rare. Several hypotheses have been of Medicine, Prince of Songkla University, proposed, and the pathophysiology of coexisting tumors has long been debated; 1Department of Pathology, however, due to low incidence, standard practices for this scenario are still Abstract Faculty of Medicine, Prince inconclusive. Case Description: The authors describe 6 cases of coexisting of Songkla University, tumors. By conducting a literature research focused on the computed tomography Hat Yai, Songkhla, 90110, (CT) era and patients without prior radiation or phakomatosis. Sixty‑five such Thailand reported cases were identified. In addition, the authors summarize their experience in 6 patients including histopathological features, chronological presentations, outcomes, mortality, and management from their series as well as from previous cases from the reported literature. Conclusion: The coexistence of multiple, primary brain tumors is an interesting condition. Surgical management remains the major treatment; malignant histology has a poor prognostic factor. Keywords: Coexistence of brain tumor, diffuse astrocytoma, glioblastoma, meningioma, multiple primary brain tumor Introduction gender‑specific distribution, the incidence rate of tumor he association of multiple, primary brain tumors of the meninges is higher in females (10.51/100,000) T with different histology occurring simultaneously rather than in males (4.85/100,000), while the in the same patient is an extremely rare condition.
    [Show full text]
  • An Elderly Woman
    Self-assessment corner 827 1 Ridolfi RL, Bell WR. Thrombotic thrombocytopenic 4 Rose M, Eldor A. High incidence of relapses in thrombotic purpura. Report of 25 cases and review of the literature. thrombocytopenic purpura. Am J Med 1987; 83: 437-44. Medicine 1981; 60: 413-28. 5 Ridolfi RL, Hutchins GM, Bell WR. The heart and cardiac 2 Bell Wr, Braine HG, Ness PM, Kuckler TS. Improved conduction system in thrombotic thrombocytopenic pur- Postgrad Med J: first published as 10.1136/pgmj.73.866.827 on 1 December 1997. Downloaded from survival in thrombotic thrombocytopenic purpura-hemo- pura. A clinicopathological study of 17 autopsied patients. lytic uremic syndrome: clinical experience in 108 patients N Ann Intern Med 1979; 9: 357 - 63. Engl J Med 1991; 325: 398-403. 6 Eagle KA, Fallon JT. A 41-year-old woman with 3 Harrison CN, Lawrie AS, Iqbal A, Hunter A, Machin SJ. thrombocytopenia, anemia, and sudden death. N Engl JT Plasma exchange with solvent/detergent-treated plasma of Med 1994; 331: 661-7. resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996; 94: 756-8. Epigastric pain and a left upper quadrant mass in an elderly woman R Joarder, AC Harris, M Gibson, A Al-Kutoubi An 81-year-old woman presented to her general practitioner complaining of epigastric discomfort radiating to her back. This was associated with weakness, fatigue, diarrhoea, and a microcytic anaemia (haemoglobin 8.6 g/dl). On examination, she was found to have a smooth mass in the left hypochondrium. Upper gastrointestinal tract endoscopy was normal. An abdominal ultrasound scan showed an 11 x 7 x 5 cm mass in the left hypochondrium which had air running through it.
    [Show full text]
  • Tuberous Sclerosis Epilepsy and Psychosis by Adults
    Journal of Neurology & Stroke Short Communication Open Access Tuberous sclerosis epilepsy and psychosis by adults Introduction Volume 8 Issue 6 - 2018 The tuberous sclerosis (TS) or tuberous sclerosis complex (TSC) is a multisystem, autosomal dominant disorder by children and adults, Andrej N Ilanković,1 NikolaN Ilanković2 results from mutations in one of two genes, TSC1 (encoding hamartin) 1Universitz Psychiatric Clinic, Dep. of Neuropszchiatrz, Serbia or TSC2 (encoding tuberin). First described in depth by Bourneville in 2General hospital “MEDIGROUP”, Serbia 1880 (Morbus Bourneville, Epiloa).1 TS and TSC often causes disabling neuropsychiatric disorders, Correspondence: Andrej N. Ilanković, MD, PhD, Ass Prof, including epilepsy, mental retardation, autism and psychosis. Universitz Psychiatric Clinic, Dep. of Neuropszchiatrz, Belgrade, Serbia, Pasterova 2, Email Additional major features of the disease include dermatologic manifestations such as facial angiofibromas, renal angiomyolipomas, Received: October 09, 2018 | Published: December 26, 2018 and pulmonary lymphangiomyomatosis. TSC has a wide clinical spectrum of disease, and many patients have minimal signs and symptoms with or without neurologic and psychiatric disability.2 TS is one of “phakomatosis” a group of congenital hereditary developmental anomalies having selective involvement of tissues of ectodermal origin, which develop disseminated glial hamartomas. Examples of phakomatosis are neurofibromatosis, tuberous sclerosis, DERMATOLOGICAL LESIONS Sturge-Weber syndrome, and von Hippel-Lindau disease.”3 Shagrin patch Papula Hypomelanic macula Angiofibroma Figure 2 Typical endocranial (cortical, subcortical and subependymal) lesions by Tuberous sclerosis. The molecular genetics analysis in multigenerational families and positional cloning were used to map both the TSC1 and TSC2 genes 32- 34 . The TSC2 gene, which is located on chromosome 16p13, encodes Figure 1 Typical skin lesion for Tuberous sclerosis.
    [Show full text]